Thymus Exclusivity: All the Right Conditions for T Cells  by Iwasaki, Hiromi & Akashi, Koichi
of other cytokines are in the IL-10 family (IL-19, IL-20, IL-
22, and IL-26), and the extent to which they depend
upon Tyk2 was not evaluated.
A difference noted in the present study versus
what was seen in cells from Tyk2-deficient mice is re-
sponsiveness to IL-6. IL-6 signaling in the mouse ap-
pears to be Tyk2-independent, whereas IL-6 signaling
in the patient cells was partially Tyk2 dependent. This
is of interest because IL-6 utilizes the gp130 receptor
chain, which is common to a large family of cytokines
including IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM),
ciliary neurotrophic factor, cardiotrophin-1, cardiotro-
phin-like cytokine, and leukemia inhibitory factor (LIF).
More studies will be needed to determine which, if
any, other gp130 cytokine members are affected by
Tyk2 deficiency and whether these deficits are clinically
relevant.
In conclusion, the ‘‘experiment of nature’’ described
herein clearly establishes the critical role of Tyk2 in hu-
mans, and the signaling defects found correlate well with
the clinical presentation. How common is this disorder?
Apparently, not very common; in fact, the authors care-
fully point out that this genetic lesion may be the determi-
nant for only a subset of patients with recessive HIES.
Notably, the autosomal-dominant form of HIES is asso-
ciated with skeletal abnormalities, and it is clear that this
is a distinct clinical entity. However, the findings are also
of potential interest with respect to the development of
immunosuppressive drugs. Because Jak3 deficiency is
associated with profound immunodeficiency, consider-
able effort has been exerted in developing a clinically
useful Jak3 antagonist (Changelian et al., 2003). Such
a drug has been developed and is currently being stud-
ied in clinical trials in the setting of transplant rejection,
rheumatoid arthritis, and psoriasis. Given that the devel-
opment of a selective Jak antagonist is feasible and
given the emerging information on the IL-23 and IL-17
axes in immune-mediated disease, development of
a Tyk2 inhibitor appears to be a reasonable strategy.
Like all other immunosuppressive drugs, a Tyk2 inhibitor
would not be without risks. Analysis of Tyk2-deficient
patients can give clues as to what to expect in humans
treated with a Tyk2 antagonist.
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697Thymus Exclusivity:
All the Right Conditions
for T Cells
A fraction of primitive ‘‘lymphoid’’ precursors retain
plasticity for myeloid differentiation. In this issue of
Immunity, Laiosa et al. describe that Notch-Delta
signals can protect thymic precursors from repro-
gramming into the myeloid lineage, antagonizing the
enforced myeloid transcription factors such as PU.1
and C/EBPa.
For efficient T cell production, primitive hematopoietic
progenitors require the influence of the thymic micro-
environment. However, the progenitor population thatdirectly seeds the thymus is still controversial (Traver
and Akashi, 2004). In the bone marrow, at least three in-
dependent ‘‘lymphoid’’ progenitor subsets are respon-
sible for seeding the thymus to develop T cells. These
include IL-7Ra+Sca-1loc-Kitlo common lymphoid pro-
genitors (CLPs), IL-7Ra+pTa+B220+CD192c-Kit2 cells
(CLP-2), and IL-7Ra2RAG1+Sca-1+c-Kit+ earliest lym-
phocyte progenitors (ELPs), all of which possess robust
T cell potential in vivo (Figure 1; Traver and Akashi, 2004).
Although CLPs do not generate granulocyte-monocyte
(GM) lineage cells, RAG1-expressing ELPs still possess
a minor GM potential. Immediately after intravenous
transplantation of whole bone marrow cells into irradi-
ated hosts, a substantial fraction of thymic immigrants
contains progenitors with GM potential (Mori et al.,
2001). In the steady-state thymus, the CD252CD44+c-
Kit+ early thymic progenitor subset that should contain
Immunity
698Figure 1. T Cell Lineage Restriction from Multipotent Hematopoietic Stem Cells
In the bone marrow, hematopoietic stem cells give rise to a variety of phenotypically identifiable myeloid and lymphoid progenitors. At least five
independent populations might be able to seed the thymus. Multipotent progenitors (MPPs) with short-term reconstituting activity can differen-
tiate into all lymphoid and myeloid cells. Three ‘‘lymphoid’’ progenitor fractions, the common lymphoid progenitor (CLP), the CLP-2, and the ear-
liest lymphoid progenitor (ELP), were purified based on the expression of IL-7Ra, Rag1, and pTa (Traver and Akashi, 2004). These three lymphoid
progenitor subsets display robust T and B cell reconstitution activity, whereas ELPs retain minor GM potential. The committed T cell progenitor
(CTP) can also be isolated in the bone marrow. All five populations can home to the thymus because they generate T cells after intravenous trans-
plantation. In the thymus, the primitive DN1 fraction contains the early thymocyte precursor (ETP). ETPs and DN1 cells are early progenies of
thymus-seeding cells. The majority of DN1 cells express myeloid genes such as PU.1, C/EBPa, and the lys-GFP knockin reporter, and a fraction
of them can differentiate into myeloid cells in vitro. Both the thymic DN1 and the bone marrow CLP show plasticity for myeloid development with
enforced expression of transcription factors such as PU.1 and C/EBPa. In the thymic microenvironment, Notch signaling prevents thymic immi-
grants from committing into the GM (and B cell) lineages by antagonizing PU.1 and C/EBPa (Laiosa et al., 2006). MegE, megakaryocyte and eryth-
rocyte; GM, granulocyte and monocyte; CMP, common myeloid progenitor; GMP, granulocyte and monocyte progenitor; MEP, megakaryocyte
and erythrocyte progenitor.the IL-7Ra2/loc-Kit+ early T cell progenitor (ETP) fraction
has a heterogeneous expression pattern for IL-7a,
RAG1, or pTa at the single-cell level (H.I., unpublished
data), and displays minor myelo-erythroid potential. Fur-
thermore, lymphoid-committed progenitors such as the
CD252CD44+ (DN1) thymocyte and the bone marrow
CLP possess plasticity for myelo-erythroid differentia-
tion by ectopic IL-2Rb signaling (Kondo et al., 2000) or
by combinatory action of enforced transcription factors
including GATA-1, GATA-2, and C/EBPa (Iwasaki et al.,
2006; Traver and Akashi, 2004). These results collectively
suggest that a wide range of bone marrow precursors at
different stages of hemato-lymphoid development seed
the thymus and that at least a fraction of these cells retain
myeloid potential at the time of homing (Figure 1). Thus,
the thymus might have functional microenvironment
to selectively induce T cell lineage differentiation from
these multi- or oligopotent thymic immigrants.
In this issue of Immunity, Laiosa et al. report that the
thymus provides a microenvironmental signal through
Notch, a receptor type transcription factor, in order to
attenuate GM differentiation program of thymic precur-
sors (Laiosa et al., 2006). They first show that the DN1
thymic precursor subset expresses C/EBPa, C/EBPb,
and PU.1, representative myeloid-related transcriptionfactors. The expression of C/EBPs and PU.1 are highest
in the DN1 population but gradually decline along with
thymic T cell maturation. C/EBPs and PU.1 expressed
in DN1 cells may be functional, becausew50% of these
cells (but not the more mature CD25+CD442 [DN3] or
CD252CD442 [DN4] cells) activated the EGFP knockin
reporter for the gene encoding lysozyme M (lys-GFP),
a critical myeloid target of these transcription factors.
Furthermore, the retroviral transduction of C/EBPs or
PU.1 in DN1 thymocytes induced their conversion into
macrophages and dendritic cells at the expense of T cell
differentiation. Macrophages derived from DN1 cells
possessed polyclonal VDJ rearrangements of Tcrb
gene and activation history of T cell-specific Lck gene,
providing formal evidence for their GM conversion from
T cell-committed precursors. The similar GM conver-
sion was observed in CLPs or the c-Kit+ DN1 thymo-
cytes expressing ectopic GM-CSFR (Traver and Akashi,
2004), one of the target genes of PU.1 transactivation.
These data suggest that although C/EBPs and PU.1 are
expressed at the DN1 stage, these myeloid transcription
factors need to decline for DN1 cells to be fixed to the
T cell lineage. Recent studies also showed that a proper
downregulation of PU.1 is critical for fetal thymic devel-
opment (Anderson et al., 2002; Franco et al., 2006). PU.1
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699is indispensable for fetal thymic proT cell development,
but the consistent expression of retrovirally transduced
PU.1 blocked differentiation, cell survival, and prolifera-
tion of CD25+CD44+ pro-T (DN2) cells, suggesting that
PU.1 is required to be inactive at the DN2 stage.
An important mechanism for inhibition of PU.1 and C/
EBPs in the thymus is then presented (Laiosa et al.,
2006). Notch-Delta signaling is a critical cue for promo-
tion of thymic T cell development (Radtke et al., 1999).
On OP9-DL1 stromal cells that express Delta-like 1,
a Notch ligand, both murine and human multipotent pro-
genitors preferentially read out the T cell lineage fate.
The successful induction of T cell development on the
OP9-DL1 stroma has been interpreted as the Notch-
Delta signaling instructing T cell commitment. Interest-
ingly, Notch-Delta signaling can counteract the GM pro-
gram in thymic precursors (Laiosa et al., 2006). On the
OP9-DL1 stromal layer, the morphological GM conver-
sion of DN1 thymocytes instructed by the enforced C/
EBPs and/or PU.1 is inhibited, and both the induction
of CD11b and the downregulation of Thy-1 in PU.1-
transduced thymocytes are abolished. This counterac-
tion against C/EBPa and PU.1-induced GM reprogram-
ming are also observed by retrovirally transducing the
IC-Notch, an active intracellular form of Notch1. Thus,
the thymus might provide environmental signaling for
T cell specification: the membrane-bound Notch ligands
might activate lineage-exclusive signals for GM devel-
opment in thymic precursors, overcoming the myeloid
instructive signals of PU.1.
The similar counteraction of Notch on PU.1 signaling
has also been reported in fetal thymic precursors trans-
duced with PU.1 (Franco et al., 2006). In this report, the
transactivation of Id2 (inhibitor of DNA binding 2) and
the repression of c-Myb induced by the enforced PU.1
are canceled by Notch-Delta signaling, whereas the
activation of M-CSFR and CD11b by PU.1 is barely af-
fected. Accordingly, the Notch-Delta counteraction
against PU.1 might not operate in a one-to-one corre-
spondence manner but may work in the context of
transcription factor networks. The inhibitory effect of
Notch-Delta on GM conversion driven by C/EBPa could
be partly through an antagonistic Notch-Delta signaling
on PU.1, because CD11b induction by C/EBPa is de-
pendent on PU.1 upregulation: PU.1-deficient thymo-
cytes failed to express CD11b upon C/EBPa transduc-
tion (Laiosa et al., 2006). Interestingly, the enforced
expression of GATA-3, a T cell-related transcription
factor, inhibits the Thy-1 downregulation but not CD11b
induction in DN1 thymocytes transduced with C/EBPa,
whereas E47, a product of E2A gene, does not exert
any antagonistic effects to C/EBPa. These results again
suggest that instead of the simple Notch versus PU.1
scheme, a more complex network involving multiple
transcription factors should operate to properly regu-
late thymic lymphopoiesis.
Only a minority of normal thymic precursors can differ-
entiate into the myeloid lineage fate in vitro. In contrast,
almost half of DN1 cells expressed the lys-GFP reporter,
and the lys-GFP+ and lys-GFP2 DN1 fractions equally
generated T cells on the OP9-DL1 stromal layer (Laiosa
et al., 2006). In our hands, more than 80% of DN1 cells
expressed the GFP reporter that was knocked into the
PU.1 locus (H.I., unpublished data). Although C/EBPaexpression in DN1 cells has not been evaluated at the
single-cell level, the percentage of thymic precursors ex-
pressing PU.1 or lys-GFP does not correlate with that of
cells with natural myeloid potential within the purified
DN1 fraction. A possible explanation for this discrepancy
is that the expression of lysozyme M, PU.1, and C/EBPa
in DN1 cells may reflect their myeloid potential at the time
of homing because multipotent progenitors coexpress
genes related to multiple lineages prior to commitment
(Hu et al., 1997). Therefore, in steady-state hematopoie-
sis, the expression of PU.1 and C/EBPa may not be suf-
ficient for the majority of thymic precursors to commit
into the GM lineage. It is difficult to measure what percent
of immigrating thymic progenitors are multipotent, be-
cause thymic immigrants might receive myeloid-exclud-
ing Notch-Delta signaling immediately after homing. One
could expect that mice deprived of Notch signaling have
a higher number of myeloid and B cells. In fact, in mice
conditionally disrupted with Notch1 (Radtke et al.,
1999) or RBP-J, a mediator for transcriptional activation
of all Notch receptors, thymic precursors failed to de-
velop T cells, alternately giving rise to B cells in the thy-
mus. An interpretation of this phenomenon could be that
thymic precursors immigrating from the bone marrow
may at least be bipotent for T and B cells. The number
of myeloid cells in the thymus was not assessed in these
papers, but it is possible that myeloid cells cannot ex-
pand substantially in the thymus where lymphoid but
not myeloid cytokines are abundant. Although it is diffi-
cult to assess the impact of Notch-Delta signaling ex-
cluding GM lineage differentiation in normal thymic lym-
phopoiesis, this environmental signal for selective T
lymphopoiesis may be critical at least under hematopoi-
etic stress (Mori et al., 2001).
Mice disrupted with PU.1 lack B cells in addition to
GM cells, indicating that this factor plays an essential
role in B cell generation. The conditional disruption of
PU.1, however, has revealed that PU.1 is indispensable
for development of CLPs, but not for the late B cell dif-
ferentiation after the proB cell stage. It is thus tempting
to speculate that Notch-Delta signaling also exerts
a ‘‘lineage-exclusive’’ effect on B cell development at
the CLP (and/or ELP) stage by counteracting PU.1 func-
tions, resulting in the generation of committed T cell
progenitors (CTPs) in the bone marrow (Dejbakhsh-
Jones et al., 2001), which can give rise to T cells in the
absence of thymus. In the thymus, where the mem-
brane-bound Notch ligands are ubiquitously expressed,
multipotent immigrants may be rapidly specified into
the T cell lineage, by attenuating GM and B lineage
developmental programs. Laiosa et al. show that the
thymus can display this exclusivity via Notch signaling
even against myeloid reprogramming driven by en-
forced myeloid transcription factors.
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